|Videos|May 8, 2023
Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC
Author(s)Andrew J. Armstrong, MD, Matthew Manning, MD
Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.
Advertisement
Episodes in this series
Advertisement
Related to this article
Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
lan M. Thompson Jr, MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Frequently Asked Questions on the Evolving Management of Early-Stage HER2+ Breast Cancer
4
Dr Garg on a Phase 3 Study of Proton Therapy in Head and Neck Cancer
5